Overview

Evolocumab Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI

Status:
Not yet recruiting

Trial end date:
2029-01-30

Target enrollment:

Participant gender:

Summary

The primary objective was to evaluate the effect of evolocumab (initiated within 4 h from PCI for the culprit lesion) with high-intensity statin treatment, compared to placebo with high-intensity statin treatment, on cardiovascular events (including cardiovascular death, myocardial infarction, stroke or transit ischemic attack, re-hospitalization due to unstable angina or heart failure, or any ischemia-driven coronary revascularization) in patients with acute coronary syndrome and multiple lesions.

Phase:

N/A

Details

Lead Sponsor:

Nanjing First Hospital, Nanjing Medical University

Collaborators:

Nanjing Medical University
National Natural Science Foundation of China

Treatments:

Evolocumab
Hydroxymethylglutaryl-CoA Reductase Inhibitors